The department's research in Endothelial Cell Biology, including the role of nitric oxide in sepsis, is led by Dr. Robert Danner.
Dr. Daniel Chertow's translational research program seeks to improve understanding of the pathophysiology and molecular pathogenesis and guide improved clinical management of High Consequence Pathogens including Influenza A, Ebola, and Zika viruses.
Research investigating Lung Inflammation is led by Dr. Anthony Suffredini.
Research investigating Lung Inflammation is also led by Dr. Torabi-Parizi.
Dr. Sameer Kadri founded and leads the NIH Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI), a collaborative between the NIH Clinical Center, Intramural NIAID, the CDC and Harvard Medical School.
Dr. Joseph Kovacs's research lab is the first to have sequenced the genomes of multiple Pneumocystis species, which will lead to dramatic advances in understanding the biology of the organism.
CCMD has developed a cohort of patients with Pulmonary Hypertension and has an integrated program with in vitro, small animal, and human studies. This research effort is led by Dr. Jason Elinoff.
Dr. Michael Solomon set-up and co-directs the Pulmonary Arterial Hypertension Translational Research Section. His research interests include endothelial cell dysfunction and inflammation in pulmonary arterial hypertension, and organizational structures and outcomes in the delivery of critical care cardiology.
Dr. Charles Natanson's research lab focuses on large and small animal models of Sepsis to study the pathogenesis of—and new therapeutic interventions for—septic shock.
Our Publications.